Trial Profile
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 01 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Aug 2010 NeoPharm estimates this trial may be completed by the fourth quarter of this year, as reported in a company media release.
- 20 Aug 2010 New source identified and integrated (ClinicalTrials.gov, NCT01186731)